{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:07:01Z","timestamp":1790802421341,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003061","name":"Erasmus Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003061","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejca.2026.117038","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:02:19Z","timestamp":1789052539000},"page":"117038","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Sentinel lymph node biopsy in melanoma: Redundant in the neoadjuvant era"],"prefix":"10.1016","volume":"247","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8001-1311","authenticated-orcid":false,"given":"Antonius W.","family":"Schurink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine C.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9870-8931","authenticated-orcid":false,"given":"Peter L.","family":"van Hulst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hester F.","family":"Lingsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis","family":"Verhoef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8293-6002","authenticated-orcid":false,"given":"Dirk J.","family":"Gr\u00fcnhagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejca.2026.117038_bib1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2024.11.006","article-title":"Cutaneous melanoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"36","author":"Amaral","year":"2025","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2026.117038_bib2","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa1310460","article-title":"Final trial report of sentinel-node biopsy versus nodal observation in melanoma","volume":"370","author":"Morton","year":"2014","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ejca.2026.117038_bib3","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1080\/14737140.2018.1489246","article-title":"The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care","volume":"18","author":"Keung","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"issue":"23","key":"10.1016\/j.ejca.2026.117038_bib4","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","article-title":"Completion dissection or observation for sentinel-node metastasis in melanoma","volume":"376","author":"Faries","year":"2017","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ejca.2026.117038_bib6","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.117038_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114327","article-title":"Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 \/ KEYNOTE-054 trial","volume":"211","author":"Eggermont","year":"2024","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2026.117038_bib8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ejca.2026.117038_bib9","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.ejca.2026.117038_bib10","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","article-title":"Neoadjuvant nivolumab and ipilimumab in resectable stage iii melanoma","volume":"391","author":"Blank","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.117038_bib11","article-title":"Changing role of adjuvant therapy in stage iii melanoma","author":"Chapman","year":"2025","journal-title":"New Engl J Med"},{"issue":"19","key":"10.1016\/j.ejca.2026.117038_bib12","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage iii melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.117038_bib13","unstructured":"Lucas M.W., Menzies A.M., Dimitriadis P., et al. LBA57 - Two-year clinical update and first biomarker analyses of the phase III NADINA trial comparing neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in resectable stage III melanoma. 2025. https:\/\/cslide.ctimeetingtech.com\/esmo2025\/attendee\/confcal\/show\/session\/124 (accessed 27-10-2025 2025)."},{"issue":"11","key":"10.1016\/j.ejca.2026.117038_bib14","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","article-title":"Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma","volume":"24","author":"Blank","year":"2018","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.ejca.2026.117038_bib15","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/j.ejso.2017.07.003","article-title":"Complications following completion lymphadenectomy versus therapeutic lymphadenectomy for melanoma - a systematic review of the literature","volume":"43","author":"Moody","year":"2017","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2026.117038_bib16","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ejso.2016.06.407","article-title":"Complications of sentinel lymph node biopsy for melanoma - a systematic review of the literature","volume":"43","author":"Moody","year":"2017","journal-title":"Eur J Surg Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2026.117038_bib17","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41591-022-01851-x","article-title":"Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial","volume":"28","author":"Reijers","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2026.117038_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115141","article-title":"Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: comparison of 3-year data from PRADO and OpACIN-neo","volume":"214","author":"Reijers","year":"2025","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2026.117038_bib19","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S1470-2045(24)00076-7","article-title":"Development and validation of a novel model to predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: an international, retrospective, multicentre analysis","volume":"25","author":"Stassen","year":"2024","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2026.117038_bib20","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1200\/JCO.23.01020","article-title":"PredictIng Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: the MIA calculator","volume":"42","author":"Varey","year":"2024","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2026.117038_bib21","article-title":"Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma","volume":"7","author":"Dinnes","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"24","key":"10.1016\/j.ejca.2026.117038_bib22","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1200\/JCO.19.02362","article-title":"Improved risk prediction calculator for sentinel node positivity in patients with melanoma: the melanoma institute australia nomogram","volume":"38","author":"Lo","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117038_bib23","unstructured":"Sondak V.K., Patel S.P., Othus M., et al. 1601O - 3-year survival with neoadjuvant-adjuvant pembrolizumab from SWOG S1801. 2025."},{"issue":"1","key":"10.1016\/j.ejca.2026.117038_bib24","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1046\/j.1365-2133.2002.04867.x","article-title":"Metastatic pathways and time courses in the orderly progression of cutaneous melanoma","volume":"147","author":"Meier","year":"2002","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.ejca.2026.117038_bib25","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/SLA.0000000000000500","article-title":"Outcome following sentinel node biopsy plus wide local excision versus wide local excision only for primary cutaneous melanoma: analysis of 5840 patients treated at a single institution","volume":"260","author":"van der Ploeg","year":"2014","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejca.2026.117038_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115055","article-title":"Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy","volume":"212","author":"Woodford","year":"2024","journal-title":"Eur J Cancer"},{"issue":"10336","key":"10.1016\/j.ejca.2026.117038_bib27","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","article-title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial","volume":"399","author":"Luke","year":"2022","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ejca.2026.117038_bib28","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1038\/s41591-023-02583-2","article-title":"Adjuvant nivolumab in resected stage IIB\/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial","volume":"29","author":"Kirkwood","year":"2023","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.ejca.2026.117038_bib29","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.surg.2015.12.002","article-title":"Prognostic factors in melanoma patients with tumor-negative sentinel lymph nodes","volume":"159","author":"Egger","year":"2016","journal-title":"Surgery"},{"issue":"11","key":"10.1016\/j.ejca.2026.117038_bib30","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1001\/jamadermatol.2023.3256","article-title":"Stage-specific risk of recurrence and death from melanoma in Denmark, 2008-2021: a national observational cohort study of 25\u00a0720 patients with stage ia to iv melanoma","volume":"159","author":"Helvind","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2026.117038_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(26)00026-4","article-title":"Assessment of survival benefit from sentinel node biopsy for melanoma: a systematic review and meta-analysis","author":"Varey","year":"2026","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2026.117038_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(26)00180-4","article-title":"International melanoma consortium g. on the survival benefit from sentinel node biopsy for melanoma","volume":"27","author":"Grunhagen","year":"2026","journal-title":"Lancet Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926008191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926008191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:33:06Z","timestamp":1790800386000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926008191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":31,"alternative-id":["S0959804926008191"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117038","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sentinel lymph node biopsy in melanoma: Redundant in the neoadjuvant era","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"117038"}}